Steve Miller - 26 Aug 2025 Form 4 Insider Report for CATALYST PHARMACEUTICALS, INC. (CPRX)

Role
Chief Op. & Scientific Officer
Signature
/s/ Steve Miller
Issuer symbol
CPRX
Transactions as of
26 Aug 2025
Net transactions value
-$1,828,200
Form type
4
Filing time
28 Aug 2025, 17:00:21 UTC
Previous filing
19 Feb 2025
Next filing
24 Nov 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Miller Steve Chief Op. & Scientific Officer 355 ALHAMBRA CIRCLE, SUITE 801, CORAL GABLES /s/ Steve Miller 28 Aug 2025 0001402535

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CPRX Common stock, par value $0.001 per share Options Exercise $257,600 +115,000 +12% $2.24 1,064,663 26 Aug 2025 Direct
transaction CPRX Common stock, par value $0.001 per share Sale $2,332,200 -115,000 -11% $20.28 949,663 26 Aug 2025 Direct F1, F2
transaction CPRX Common stock, par value $0.001 per share Options Exercise $246,400 +110,000 +12% $2.24 1,059,663 27 Aug 2025 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CPRX Options to purchase common stock Options Exercise $0 -115,000 -7.5% $0.000000 1,409,509 26 Aug 2025 Common Stock 115,000 $2.24 Direct F3
transaction CPRX Options to purchase common stock Options Exercise $0 -110,000 -7.8% $0.000000 1,299,509 27 Aug 2025 Common Stock 110,000 $2.24 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Shares were sold on the open market to fund the exercise price and estimated taxes due from Reporting Person as a result of the exercise of the 225,000 stock options reported on Table II.
F2 Represents a weighted average sale price. Shares were sold in a range from $20.04 to $20.645 per share.
F3 Derivative Securities vested in three annual tranches beginning on December 18, 2019.